跳至主要内容
临床试验/NL-OMON53650
NL-OMON53650招募中不适用

Short-course aminoglycosides as adjunctive treatment in adults with sepsis - SAGA

niversitair Medisch Centrum Utrecht0 个研究点目标入组 3,140 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
3,140

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1) Age >= 18 years
  • 2) Presenting to the ER
  • 3) Suspicion of bacterial infection of unknown origin, primary suspected
  • urinary origin or primary suspected abdominal origin.
  • 4) National Early Warning Score (NEWS) >= 5.
  • 5) Requiring intravenous antibiotic treatment and hospitalization.

排除标准

  • 1) Working diagnosis at the ED of pneumonia (even if other foci are mentioned
  • in the differential diagnosis).
  • 2) Chemotherapy induced neutropenia as this is considered a separate entity in
  • the guidelines.
  • 3) History of renal transplantation or pre-existing renal failure defined as a
  • GFR < 30, due to a relative contra-indication for aminoglycosides.
  • 4) Allergy for cephalosporins or aminoglycosides, known prior to the start of
  • antibiotic treatment.
  • 5) Pre-existing hearing impairment known at the moment of presentation in the
  • 6) History of heart-, lung or liver transplantation.
  • 7) Known myasthenia or botulism.
  • 8) A patient who has had an indwelling catheter for a prolonged period or was
  • catheterized intermittently, because of the recommended empirical treatment
  • including an aminoglycoside according to the SWAB guidelines.
  • 9) Use of the medication cyclosporine, cisplatin, neuromuscular acting muscle
  • relaxants, oral neomycin and oral paromomycin due to relative contra-indication
  • for aminoglycosides.
  • 10) Known colonization with a 3rd generation cephalosporin resistant bacterium
  • including Pseudomonas, relevant in the context of the infection the patient is
  • admitted with.

研究者

发起方
niversitair Medisch Centrum Utrecht

相似试验